Stay updated with breaking news from Cll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.
Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.
Stable peripheral disease levels lasting 12 months were reported in patients with treatment-naïve chronic lymphocytic leukemia following 6 years of continuous treatment with ibrutinib.
CURE looks back on some of the most important stories in the chronic lymphocytic leukemia space from 2023.
Patients with chronic lymphocytic leukemia treated with Imbruvica plus Venclexta demonstrated a healthy immune profile over time in addition to reduction in CLL disease burden.